Executive Officers

Jim Tananbaum, 57
President, Chief Executive Officer and Director

Dr. Tananbaum is also the chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm, which he founded in 2011. Dr. Tananbaum also serves as a director of Gemini Therapeutics, Inc. (Nasdaq: GMTX) (formerly FS Development Corp., a blank check company sponsored by an affiliate of Foresite Capital), since June 2020. He previously served as President, Chief Executive Officer and a director of FS Development Corp. (now Gemini Therapeutics, Inc., Nasdaq: GMTX) from June 2020 until its merger with Gemini in February 2021, and since August 2020 he also served as President, Chief Executive Officer and a Director of FS Development Corp. II (Nasdaq: FSII) Prior to founding Foresite Capital, Dr. Tananbaum served as Co-Founder and Managing Director of Prospect Venture Partners L.P. II and III, healthcare venture partnerships, from 2000 to 2010. Dr. Tananbaum was also the Founder of GelTex, Inc. in 1991, an intestinal medicine pharmaceutical company acquired by Sanofi-Genzyme, and Theravance, Inc. in 1997 (now Theravance Biopharma, Inc., a diversified biopharmaceutical company focused on organ-selective medicines, and Innoviva, Inc., a respiratory-focused healthcare asset management company partnered with Glaxo Group Limited). Dr. Tananbaum received a B.S. and a B.S.E.E. from Yale University in Applied Math and Computer Science, and an M.D. and an M.B.A. from Harvard University.

Dennis Ryan, 65
Chief Financial Officer

Since 2011, Mr. Ryan has also led the Operations Group at Foresite Capital as Chief Financial Officer and Managing Director, and is also the Chief Financial Officer of FS Development Corp. II (Nasdaq: FSII), since August 2020. He previously served as Chief Financial Officer of FS Development Corp. (now Gemini Therapeutics, Inc., Nasdaq: GMTX) from June 2020 until its merger with Gemini in February 2021. He currently serves as Board President of Whistlestop, a non-profit providing transportation and nutrition services to seniors. He received a B.A. from University of California, Berkeley in Economics, and an M.B.A from the University of Santa Clara. Mr. Ryan is a licensed certified public accountant in California.

Board of Directors

Vikram Bajaj, 42
Director 

Dr. Bajaj currently serves as a Managing Director at Foresite Capital, since September 2017 and as Chief Executive Officer of Foresite Labs, a healthcare and data science incubator, since October 2019. He is also an Associate Professor of Radiology (Consulting) at the Stanford University School of Medicine, since 2014, and an Affiliate Scientist of the Lawrence Berkeley National Laboratory, since 2011. Prior to joining Foresite Capital, Dr. Bajaj was the Chief Scientific Officer of GRAIL, Inc., a life sciences company developing a multi-cancer early detection test, from September 2016 to September 2017. From April 2013 to September 2016, Dr. Bajaj was the Co-Founder and Chief Scientific Officer of Verily (formerly Google Life Sciences), a research organization devoted to the study of life sciences, and served as Chair of its Scientific Advisory Board from September 2016 to September 2017. He is currently a Senior Adviser to FS Development Corp. II (Nasdaq: FSII) and is on the advisory board of UC Berkeley, College of Chemistry. Dr. Bajaj holds a B.A./M.S. from University of Pennsylvania in Biochemistry and a Ph.D. from the Massachusetts Institute of Technology in Physical Chemistry.

Alisa Mall, 43
Director

Ms. Mall is Managing Director at Foresite Capital, responsible for corporate development, long-term capital strategy, investor relations and environmental, social and governance engagement. Prior to joining Foresite Capital, from 2011 to November 2020, Ms. Mall served as Managing Director of Investments at Carnegie Corporation of New York, a philanthropic foundation supporting innovations in education, democratic engagement and international peace, and as Associate Director of Investments for Carnegie Corporation from 2009 to 2011. Ms. Mall has also been serving as director of FS Development Corp. II (Nasdaq: FSII) since February 2021. Previously, she was Director, Equity Capital Markets at Tishman Speyer Properties, a commercial real estate company, from 2007 to 2009, and an attorney with global law firm Orrick, Herrington & Sutcliffe LLP from 2004 to 2007. Ms. Mall is a member of the board of directors and governance committee of JBG Smith (NYSE: JBGS), a real estate investment trust. She also serves on the boards of the Pension Real Estate Association (PREA), Breakthrough New York and the Bronfman Fellowship, and is a member of the investment committee of UJA-Federation of New York and the advisory board of Declaration Partners, a family office. Ms. Mall received a J.D. from Stanford Law School and a B.A. in Political Science from Yale College.

Vasiliki (Vicky) Demas, 41
Director Nominee

Dr. Demas has served as Product Management Director for GRAIL, Inc. since December 2016. Prior to that, she served as one of the first five founding members and Department Head of Verily Life Sciences LLC (formerly Google Life Sciences) from August 2013 to December 2016. Dr. Demas also served as Staff Engineer and Interim Systems Engineering Lead for T2 Biosystems Inc. (Nasdaq: TTOO), a healthcare diagnostics company, from January 2008 to August 2013. Dr. Demas holds an Executive M.D. from Harvard Medical School, a Ph.D. from the University of California, Berkeley in Chemical Engineering and Physical Chemistry, and a B.S. in Chemical Engineering from University of Illinois at Urbana-Champaign.

Jeffrey Huber, 52
Director Nominee

Mr. Huber currently serves as Chairman of the board of directors of Genalyte, Inc., a healthcare diagnostics and analytics company, and as a member of the boards of directors of Electronic Arts Inc. (Nasdaq: EA), an electronic gaming company, Aldevron, LLC, a biotechnology company providing contract manufacturing and scientific services, Mammoth Biosciences, Inc., a biotechnology company focused on developing novel CRISPR applications for disease detection and research, Openwater, a biotechnology company focusing on portable medical imaging technologies, and Weta Digital Ltd., a digital visual effects company based in New Zealand. Mr. Huber served as founding Chief Executive Officer of GRAIL, Inc. from February 2016 to August 2017, and has served as a director since March 2016 and as Vice Chairman since October 2017. Mr. Huber has also served as co-founder and President of OpenCovidScreen, a non-profit organization aimed at accelerating scalable, low-cost testing solutions, since April 2020. From 2003 to 2016, Mr. Huber held various roles at Alphabet Inc. (Nasdaq: GOOG), most recently, Senior Vice President from 2008 to 2016. Prior to that, he served as Vice President of Architecture and Systems Development at eBay Inc. (Nasdaq: EBAY), as Senior Vice President of Engineering and Product Development at Excite@Home, an internet service provider, and as a Technology Consultant at McKinsey & Company, a management consulting firm. Mr. Huber also serves on the board of trustees of the Exploratorium, a museum of science, technology, and arts in San Francisco. Mr. Huber holds an M.B.A with a focus on technology strategy and economics from Harvard University Graduate School of Business, and a B.S from University of Illinois at Urbana-Champaign in Computer Engineering.

Kevin Ness, 44
Director Nominee

Dr. Ness served as the Chief Executive Officer of Inscripta, Inc., a digital genome engineering company, from November 2016 to November 2020. Prior to Inscripta, he served as Founder, Chief Technology Officer and Chief Operating Officer of 10x Genomics, Inc. (Nasdaq: TXG), a biotechnology company that designs and manufactures gene sequencing technology, from September 2012 to September 2016. Dr. Ness also co-founded QuantaLife Inc., an advanced genetic analysis company that merged with Bio-Rad Laboratories, Inc. (NYSE: BIO, BIOb) in 2011, where he served as Vice President of Product Development and director from September 2008 to September 2012. Dr. Ness holds a Ph.D. from Stanford University in Mechanical Engineering with a focus in micro-technology, micro-fluidics, micro-scale heat transfer and biology, and a M.S. and B.S. from University of California, Santa Barbara in Mechanical Engineering and Material Science.